Zokinvy
NDC 73079-075
Product Information
Zokinvy is a NDA-approved product labeled by Eiger Biopharmaceuticals, Inc.. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a yellow product. This product entry covers the primary NDC 73079-075 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
ORANGE (C48331 - OPAQUE LIGHT ORANGE)
14 MM
LNF;50
LNF;75
Code Structure Chart
Product Details
What is NDC 73079-075?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- LONAFARNIB (UNII: IOW153004F)
- LONAFARNIB (UNII: IOW153004F) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- POVIDONE (UNII: FZ989GH94E)
- POLOXAMER 188 (UNII: LQA7B6G8JG)
- CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)
- SILICON DIOXIDE (UNII: ETJ7Z6XBU4)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2467582 - lonafarnib 50 MG Oral Capsule
- RxCUI: 2467588 - Zokinvy 50 MG Oral Capsule
- RxCUI: 2467588 - lonafarnib 50 MG Oral Capsule [Zokinvy]
- RxCUI: 2467590 - lonafarnib 75 MG Oral Capsule
- RxCUI: 2467592 - Zokinvy 75 MG Oral Capsule
* Please review the full disclaimer at the bottom of this page.
Patient Education
Lonafarnib
Lonafarnib is used to reduce the risk of death in children 1 year of age or older with Hutchinson-Gilford progeria syndrome (HGPS, Hutchinson-Gilford syndrome; an inherited disorder that causes certain proteins to build up in the body which causes children to age rapidly). Lonafarnib is also used to treat certain processing-deficient progeroid laminopathies (PDPL; inherited disorders that cause certain proteins to build up in the body which cause children to age rapidly). Lonafarnib is in a class of medications called farnesyltransferase inhibitors. It works by preventing proteins from building up and damaging cells.
[Learn More]
* Please review the full disclaimer at the bottom of this page.